The European trial of ACR16 yields good results
ACR16 improves voluntary and involuntary movement. This is wonderful news! posted 02-03-2010
http://www.hdlighthouse.org/showUpdate.php?p_articleNumber=662
A Sirtuin Inhibitor Enters Phase1a Clinical Trials in Europe
Siena Biotech announces a safety and tolerability study with healthy volunteers, preparatory to trials in HD patients. posted 01-31-2010
http://www.hdlighthouse.org/showUpdate.php?p_articleNumber=661
Invitation to participate in a quality of life survey
Here is an opportunity to tell the medical professionals about quality of life issues. posted 12-22-2009
http://www.hdlighthouse.org/showUpdate.php?p_articleNumber=659
Synaptic activity, aggregation, and memantine
Dr. Michael Hayden and Dr. Stuart Lipton show that normal synaptic activity is neuroprotective, that extrasynaptic activity is toxic, and that memantine will suppress the later while leaving the former unaffected. posted 12-22-2009
http://www.hdlighthouse.org/showUpdate.php?p_articleNumber=651
An interview with Dr. Jan Nolta
A trial of mesenchymal stem cell is planned for the end of 2010. posted 12-06-2009
http://www.hdac.org/features/article.php?p_articleNumber=657
An interview with Dr. Jan Nolta
A trial of mesenchymal stem cell is planned for the end of 2010. posted 12-06-2009
http://www.hdlighthouse.org/showUpdate.php?p_articleNumber=657
The RCAN1 gene and HD
Overexpression of the RCAN1 gene may be a treatment for Huntington's Disease. posted 12-05-2009
http://www.hdlighthouse.org/showUpdate.php?p_articleNumber=630
The search for genetic modifiers
The search for genetic modifiers is an important part of the effort to find treatments. posted 12-05-2009
http://www.hdlighthouse.org/showUpdate.php?p_articleNumber=652
Track-HD reports baseline findings
Baseline findings indicate clear differences that fall on a continuum from the control group to gene carriers predicated to be farther from onset, carriers closer to onset, those in very early stages, and those somewhat later in progression. posted 12-05-2009
http://www.hdlighthouse.org/showUpdate.php?p_articleNumber=653
Cogane
A new BDNF inducer enters the pipeline. posted 12-05-2009
http://www.hdlighthouse.org/showUpdate.php?p_articleNumber=654
Mesenchymal stem cells repair neurotoxin damage in an animal model
Preclinical work supports the use of mesenchymal stem cells to treat neurodegenerative disorders. posted 12-05-2009
http://www.hdlighthouse.org/showUpdate.php?p_articleNumber=655
Sub Cortical Front Dementia in Huntington's Disease
There is a very pressing need to frankly discuss one of the most debilitating symptoms in the neuropsychiatric sequelae of “softer” symptoms in Huntington’s Disease- sub-cortical “frontal” dementia. posted 11-01-2009
http://www.hdac.org/features/article.php?p_articleNumber=637
Managing Medications from a Caregiver's Perspective
Medications are one of the most difficult issues facing Huntington’s Disease (HD) caregivers and patients posted 09-20-2009
http://www.hdac.org/features/article.php?p_articleNumber=649
Axonal transport impaired in HD
Researchers have identified the mechanism by which axonal transport is impaired in neurons in HD. posted 09-20-2009
http://www.hdlighthouse.org/showUpdate.php?p_articleNumber=650
Using Your Words
Learning how to use your words can take a lifetime to learn. It is an art that takes a lot of practice, and it all begins with the realization that the people around us are NOT mind readers. posted 09-19-2009
http://www.hdac.org/features/article.php?p_articleNumber=648
— news list provided by hdac.org —